Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T cell Therapy for Acute Lymphoblastic Leukemia

Chimeric antigen receptor (CAR)-modified T cells with anti-CD19 specificity are a highly effective novel immune therapy for relapsed/refractory acute lymphoblastic leukemia (ALL). Cytokine release syndrome (CRS) is the most significant and life-threatening toxicity. To improve understanding of CRS,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Discov
Main Authors: Teachey, David T., Lacey, Simon F., Shaw, Pamela A., Melenhorst, J. Joseph, Maude, Shannon L., Frey, Noelle, Pequignot, Edward, Gonzalez, Vanessa E., Chen, Fang, Finklestein, Jeffrey, Barrett, David M., Weiss, Scott L., Fitzgerald, Julie C., Berg, Robert A., Aplenc, Richard, Callahan, Colleen, Rheingold, Susan R., Zheng, Zhaohui, Rose-John, Stefan, White, Jason C., Nazimuddin, Farzana, Wertheim, Gerald, Levine, Bruce L., June, Carl H., Porter, David L., Grupp, Stephan A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5448406/
https://ncbi.nlm.nih.gov/pubmed/27076371
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-16-0040
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados